FY2025 EPS Estimate for CytomX Therapeutics Cut by Analyst

CytomX Therapeutics, Inc. (NASDAQ:CTMX) – Analysts at HC Wainwright dropped their FY2025 earnings per share estimates for shares of CytomX Therapeutics in a research note issued to investors on Tuesday, November 11th. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will post earnings per share of ($0.03) for the year, down from their prior forecast of $0.17. HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for CytomX Therapeutics’ current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for CytomX Therapeutics’ Q4 2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.34) EPS.

A number of other research analysts have also commented on CTMX. Weiss Ratings upgraded CytomX Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, October 8th. Oppenheimer began coverage on CytomX Therapeutics in a research note on Thursday, July 31st. They set an “outperform” rating and a $7.00 price target on the stock. Wedbush reiterated an “outperform” rating and set a $6.00 target price on shares of CytomX Therapeutics in a research report on Friday, November 7th. Cantor Fitzgerald initiated coverage on CytomX Therapeutics in a report on Monday, September 22nd. They issued an “overweight” rating and a $6.00 price objective for the company. Finally, Barclays boosted their target price on CytomX Therapeutics from $3.50 to $6.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 21st. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.67.

CytomX Therapeutics Stock Performance

Shares of NASDAQ CTMX traded down $0.28 during mid-day trading on Thursday, reaching $3.96. 1,269,286 shares of the company traded hands, compared to its average volume of 3,383,497. The stock has a market cap of $670.12 million, a PE ratio of 7.04 and a beta of 2.29. CytomX Therapeutics has a fifty-two week low of $0.40 and a fifty-two week high of $4.62. The company’s fifty day moving average is $3.07 and its two-hundred day moving average is $2.46.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.05). The company had revenue of $5.96 million during the quarter, compared to analysts’ expectations of $11.50 million. CytomX Therapeutics had a return on equity of 158.70% and a net margin of 34.04%.

Institutional Trading of CytomX Therapeutics

A number of hedge funds have recently bought and sold shares of CTMX. Jefferies Financial Group Inc. bought a new position in shares of CytomX Therapeutics in the third quarter worth $169,000. First Trust Advisors LP bought a new position in shares of CytomX Therapeutics during the third quarter valued at about $1,282,000. Dimensional Fund Advisors LP increased its position in CytomX Therapeutics by 146.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 451,128 shares of the biotechnology company’s stock valued at $1,439,000 after purchasing an additional 267,962 shares during the period. BIT Capital GmbH bought a new stake in shares of CytomX Therapeutics during the third quarter valued at approximately $52,000. Finally, Persistent Asset Partners Ltd bought a new position in shares of CytomX Therapeutics during the third quarter valued at approximately $136,000. 67.77% of the stock is currently owned by institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.